Quick Answer
Candel Therapeutics, Inc. reported Shares Outstanding of 54.90 million shares for fiscal year 2025.
Candel Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 54.90M | +17.3% |
| 2024 | 46.81M | +60.9% |
| 2023 | 29.09M | +0.6% |
| 2022 | 28.92M | +0.8% |
| 2021 | 28.69M | +146.6% |
| 2020 | 11.64M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 54.90M | +70.9% | +0.0% |
| June 30, 2025 | 54.89M | +76.7% | +11.5% |
| March 31, 2025 | 49.25M | +67.8% | +5.2% |
| December 31, 2024 | 46.81M | +60.9% | +45.7% |
| September 30, 2024 | 32.13M | +11.1% | +3.4% |
| June 30, 2024 | 31.06M | +7.4% | +5.8% |
| March 31, 2024 | 29.35M | +1.5% | +0.9% |
| December 31, 2023 | 29.09M | +0.6% | +0.6% |
- Candel Therapeutics, Inc. showed an increase of +17.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Candel Therapeutics, Inc.’s shares outstanding has grown by 371.8% (from 11.64 million shares to 54.90 million shares).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: